BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9290461)

  • 1. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
    Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
    Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas.
    Yoshida M; Ohtsuru A; Samejima T; Okazaki M; Fujishita A; Ito M; Yamashita S; Ishimaru T
    Endocr J; 1999 Feb; 46(1):81-90. PubMed ID: 10426571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis.
    Huang SC; Yu CH; Huang RT; Hsu KF; Tsai YC; Chou CY
    Obstet Gynecol; 1996 Jun; 87(6):1019-24. PubMed ID: 8649683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
    Mizutani T; Sugihara A; Nakamuro K; Terada N
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
    Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
    Wang Y; Matsuo H; Kurachi O; Maruo T
    Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma.
    Chou CY; Huang SC; Tsai YC; Hsu KF; Huang KE
    Gynecol Oncol; 1997 May; 65(2):225-31. PubMed ID: 9159329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells.
    Chen W; Yoshida S; Ohara N; Matsuo H; Morizane M; Maruo T
    J Clin Endocrinol Metab; 2005 Feb; 90(2):884-92. PubMed ID: 15536154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
    Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
    Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females.
    Brosens I; Johannisson E; Dal Cin P; Deprest J; Van den Berghe H
    Fertil Steril; 1996 Sep; 66(3):376-9. PubMed ID: 8751732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy.
    Broekmans FJ; Hompes PG; Heitbrink MA; Netelenbos CC; Roos JC; Falke TM; Schoemaker J
    Am J Obstet Gynecol; 1996 Nov; 175(5):1208-16. PubMed ID: 8942490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
    Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
    Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
    Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
    J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
    Dixon D; Flake GP; Moore AB; He H; Haseman JK; Risinger JI; Lancaster JM; Berchuck A; Barrett JC; Robboy SJ
    Virchows Arch; 2002 Jul; 441(1):53-62. PubMed ID: 12111201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.